When KDELR1 was submitted to the online tool GEPIA2, survival analyses indicated that glioma samples with KDELR1 overexpression had shorter OS and PFS (progression-free survival) times than those with low KDELR1 expression (P < 0.05; Figures 7A, B). This evidence concerns the gene KDELR1 and central nervous system cancer.